RetinalGeniX Technologies Inc. announced that Anatoly Dritschilo, M.D. has joined the Company?s Medical Advisory Board. Dr. Dritschilo is a renowned educator, inventor, translational scientist, and business executive. Dr. Dritschilo is the CEO and Chairman of the Board of Directors of Shuttle Pharmaceuticals Holdings Inc. Formerly, as an educator and translational scientist, he was employed at the Georgetown University and the MedStar Georgetown University Hospital as a radiation oncologist and chairman of the Department of Radiation Medicine.

Over a 40+ year career, he has provided clinical services to thousands of patients presenting with cancers of the breast, prostate, and the central nervous system. As a translational scientist, Dr. Dritschilo has focused his research on sensitizing cancers to ionizing radiation. He is a leader in the development of antisense oligonucleotides and small molecules directed at targets for radiation sensitization.

He has also served as Medical Director of Georgetown University Hospital from 1994 to 1997, and Interim Director of the NCI-funded Lombardi Comprehensive Cancer Center from 2005 to 2007. He has been a member of the Boards of Directors of MedStar-Georgetown University Hospital, the National Capital Rehabilitation Hospital, and the MedStar Research Institute. His 250+ scientific publications and 12 issued patents have earned him election as a Fellow of the National Academy of Inventors.

Dr. Dritschilo holds a BS degree in Chemical Engineering from the University of Pennsylvania, his medical degree from the College of Medicine of New Jersey, and residency training from the Harvard Joint Center for Radiation Therapy.